Terumo subsidiary MicroVention has launched its LVIS EVO intraluminal support device to treat wide neck intracranial aneurysms in the U.S.
Available in Europe since 2019 with over 12,000 units sold, LVIS EVO is heralded as the first fully visible, coil-assisted intracranial stent in the U.S. It offers confirmation of wall apposition thanks to enhanced visualization and its braid angle can improve device opening along its entire length, according to the company.
LVIS EVO can be resheathed up to 80% of the device length. The entire portfolio is compatible with MicroVention’s Headway 17 advanced microcatheter as well as the company’s Scepter C and Scepter XC occlusion balloons.
The device is indicated for usage with neurovascular embolization coils in adults to treat saccular intracranial aneurysms with neck width of 4 mm or greater or a dome-to-neck ratio of less than two that arise from a parent vessel with a diameter between 2 and 4.5 mm.
“Today’s announcement underscores MicroVention’s commitment to delivering groundbreaking solutions for hemorrhagic stroke treatment,” said Carsten Schroeder, president and CEO of MicroVention. “MicroVention continues to lead the way in both hemorrhagic and ischemic stroke care. This achievement is a testament to our collaboration with leading physicians worldwide. By identifying the evolving needs in patient care and transforming those insights into innovative technologies, we are able to save lives and improve outcomes.”